pipeline-prospector-insert-v1
X

Find Approved Dermatology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lidocaine,Hyaluronic Acid

            Therapeutic Area: Dermatology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Crescita Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Distribution Agreement January 20, 2020

            Details:

            The partnership with FILLMED will allow Crescita to expand its product offering in the medical aesthetic field with the addition of the hyaluronic acid ART-Filler® injectables range and NCTF® 135 HA.

            George Washington University

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aprepitant

            Therapeutic Area: Dermatology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hoth Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 15, 2020

            Details:

            Hoth used the option period to evaluate GW's unique Substance P receptor blocker (Aprepitant) that inhibited cutaneous and other neurogenic inflammation side effects that cancer patients suffer during treatment with anticancer drugs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trifarotene

            Therapeutic Area: Dermatology

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Galderma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 08, 2020

            Details:

            Certara's Simcyp population-based Simulator was used to support Galderma’s successful U.S. FDA new drug application for AKLIEF (trifarotene) Cream, 0.005% for the topical treatment of acne.